Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

377
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
377
Coronary Artery Disease III: Clinical Manifestations01:30

Coronary Artery Disease III: Clinical Manifestations

526
Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
526
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

817
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
817
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

1.7K
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
1.7K
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

1.5K
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.5K
Angina IV: Management01:26

Angina IV: Management

398
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
398

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Chronic Treatment with Renin-Angiotensin System Inhibitors at Hospital Admission is Associated with Improved Reperfusion and Mortality Among STEMI Patients Undergoing Mechanical Reperfusion: Insight from the ISACS-STEMI COVID-19 Registry.

Current vascular pharmacology·2026
Same author

Revascularization with drug-coated balloons alone in complex coronary artery disease: a systematic review.

Clinical research in cardiology : official journal of the German Cardiac Society·2026
Same author

Paclitaxel-coated balloon treatment is associated with sympathetic coronary denervation in a porcine model.

Scientific reports·2026
Same author

Ultrasound common hepatic artery denervation (CHA-D) as a novel neuromodulatory strategy for cardiovascular-kidney-metabolic syndrome: first-in-human experience.

Clinical research in cardiology : official journal of the German Cardiac Society·2026
Same author

Persisting Sex Discrepancies in Short-Term Outcomes of Patients with ST-Segment Myocardial Infarction: Results of the ISACS-STEMI COVID-19 Registry.

Journal of clinical medicine·2026
Same author

The European bifurcation club randomized trial of stepwise provisional stenting vs drug-coated balloon therapy for nonleft main true coronary bifurcations: The EBC DCB trial.

American heart journal·2026

Related Experiment Video

Updated: Mar 20, 2026

Novel Percutaneous Approach for Deployment of 3D Printed Coronary Stenosis Implants in Swine Models of Ischemic Heart Disease
06:39

Novel Percutaneous Approach for Deployment of 3D Printed Coronary Stenosis Implants in Swine Models of Ischemic Heart Disease

Published on: February 18, 2020

7.3K

Coronary Drug Coated Balloons: Clinical Applications and Data.

Bruno Scheller1, Saarraaken Kulenthiran2, Davor Vukadinovic2

  • 1Department of Internal Medicine III, Cardiology, Angiology and Intensive Care Medicine, Saarland University Hospital, Homburg, Germany; Clinical and Experimental Interventional Cardiology, Saarland University, Homburg, Germany.

Interventional Cardiology Clinics
|March 18, 2026
PubMed
Summary

Drug-coated balloons (DCB) are increasingly used for coronary de novo disease, requiring proper lesion preparation. While not replacing drug-eluting stents, DCBs are key to reducing permanent implants in vascular medicine.

Keywords:
Drug coated balloonLeaving nothing behindPaclitaxelSirolimus

More Related Videos

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

9.2K
Complete and Partial Resuscitative Endovascular Balloon Occlusion of the Aorta for Hemorrhagic Shock
06:30

Complete and Partial Resuscitative Endovascular Balloon Occlusion of the Aorta for Hemorrhagic Shock

Published on: May 19, 2022

8.2K

Related Experiment Videos

Last Updated: Mar 20, 2026

Novel Percutaneous Approach for Deployment of 3D Printed Coronary Stenosis Implants in Swine Models of Ischemic Heart Disease
06:39

Novel Percutaneous Approach for Deployment of 3D Printed Coronary Stenosis Implants in Swine Models of Ischemic Heart Disease

Published on: February 18, 2020

7.3K
Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

9.2K
Complete and Partial Resuscitative Endovascular Balloon Occlusion of the Aorta for Hemorrhagic Shock
06:30

Complete and Partial Resuscitative Endovascular Balloon Occlusion of the Aorta for Hemorrhagic Shock

Published on: May 19, 2022

8.2K

Area of Science:

  • Interventional Cardiology
  • Vascular Medicine
  • Biomaterials Science

Background:

  • Drug-coated balloon (DCB) treatment is gaining traction globally for coronary de novo disease.
  • Effective lesion preparation is a fundamental requirement for successful DCB therapy.
  • DCBs represent a significant advancement in reducing permanent implants in interventional vascular procedures.

Purpose of the Study:

  • To highlight the growing importance of DCB technology in treating coronary artery disease.
  • To emphasize the critical role of lesion preparation in DCB treatment efficacy.
  • To discuss the future trajectory of DCB technology, including optimization and innovation.

Main Methods:

  • Review of current DCB applications and their prerequisites.
  • Analysis of the role of DCBs in comparison to drug-eluting stents.
  • Exploration of future research and development directions in DCB technology.

Main Results:

  • DCB treatment is a promising alternative for coronary de novo disease, with lesion preparation being crucial.
  • DCBs are expected to reduce the need for permanent implants in vascular interventions.
  • Future advancements will focus on optimizing lesion preparation, integrating intravascular imaging and physiology, and enhancing coating technologies.

Conclusions:

  • DCB technology is poised to play a vital role in reducing permanent implants in interventional vascular medicine.
  • Continued innovation in lesion preparation, imaging, coating, and drug selection will drive the future of DCB therapies.
  • DCBs offer a valuable therapeutic option, complementing existing treatments like drug-eluting stents.